-

Agilent Signs Sponsorship Agreement with My Green Lab

Highlighting their ongoing commitment to sustainability

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today that it has become a top-level sponsor of My Green Lab, a nonprofit organization dedicated to improving the sustainability of scientific research.

Run “for scientists, by scientists,” Agilent chose My Green Lab for their knowledge of the markets and scientific fields which both organizations work within, as well as for their holistic approach to sustainability; their understanding of the interconnectivity between all the parts that make up a laboratory, from chemicals to instruments to the environment itself.

“We are increasingly aware that sustainability must be a priority topic in science, which is why I am delighted to announce our new sponsorship agreement with My Green Lab,” said Agilent CEO Mike McMullen. “Sustainability is a key consideration in all our activities, and we look forward to ultimately passing on the benefits of our efforts and innovation to our customers.”

Agilent is now working with My Green Lab to have their instruments independently audited for the organization’s Accountability, Consistency, and Transparency (ACT) label. The ACT label provides information about the environmental impact of manufacturing, using and disposing of a product and its packaging, enabling purchasers to make better informed, sustainable choices.

"We are really excited to be working with Agilent,” said Allison Paradise, CEO of My Green Lab “The fact that Agilent is willing to highlight sustainability through our ACT labeling program speaks to Agilent's leadership in this area.”

Agilent has long been committed to implementing sustainable practices throughout its operations, and organizations such as Barron’s, Forbes, and Dow Jones have ranked Agilent among the most sustainable companies in the life sciences industry.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Contacts

Catherine Kaye
Agilent Technologies
+447775 410632
catherine.kaye@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Catherine Kaye
Agilent Technologies
+447775 410632
catherine.kaye@agilent.com

More News From Agilent Technologies Inc.

Agilent Showcases Cancer Research Solutions at AACR 2026

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting on April 17–22, 2026, in San Diego, California. At the meeting, Agilent will highlight advances designed to connect discovery research, translational science, and companion diagnostics development, reflecting the growing demand f...

Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced the launch of the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation portfolio combining multimode microplate reading and high-content cell imaging in a single platform. Building on a decade of Cytation innovation and shaped by continuous customer feedback, the BioTek Cytation 9 helps laboratories move from samples to insights faster, supporting workflows from basic resea...

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying patients with esophageal or gastroesophageal junction (GEJ) carcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC 22C3 pharmDx, Code SK006, is the only FDA-approved companion diagnostic indica...
Back to Newsroom